Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NadiHN nivolumab plus postoperative radiotherapy in resectable intermediate-risk head and neck squamous cell carcinoma
2016-004787-20Phase 2Completed
- Sponsor
- University of Bonn
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University of Bonn. Primary endpoint: Disease-free survival. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2016-004787-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004787-20.